Expertise in
16
conditions
Expertise in
16
conditions
Texas Institute Of Pediatrics PLLC
4410 Medical Dr Ste 540, 
San Antonio, TX 

Overview

Vinod Gidvani is a Hematologist and an Oncologist in San Antonio, Texas. Dr. Gidvani is highly rated in 16 conditions, according to our data. His top areas of expertise are Dyserythropoietic Anemia and Thrombocytopenia, Langerhans Cell Histiocytosis, Hepatoblastoma, Reticulohistiocytoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 63 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Texas Institute of Pediatrics PLLC
4410 Medical Dr Ste 540, San Antonio, TX 78229
Other Locations
Methodist Hospital
7700 Floyd Curl Dr, San Antonio, TX 78229

Additional Areas of Focus

Dr. Gidvani has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


63 Clinical Trials

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Molecular Analysis for Therapy Choice (MATCH)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Neuroblastoma Biology Studies
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
View 42 Less Clinical Trials
Similar Doctors
Expertise in
16
conditions
Hematology | Oncology
Expertise in
16
conditions
Hematology | Oncology

Office

2829 Babcock Rd Ste 300, 
San Antonio, TX 
 (0.6 miles away)
Languages Spoken:
English
Offers Telehealth

Ildefonso Rivera is a Hematologist and an Oncologist in San Antonio, Texas. Dr. Rivera is highly rated in 16 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Gastric Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma.

Expertise in
18
conditions
Expertise in
18
conditions

University Of Texas Health Science Center At San Antonio

7979 Wurzbach Rd, 
San Antonio, TX 
 (0.5 miles away)
Languages Spoken:
English
Offers Telehealth

Andrew Brenner is an Oncologist in San Antonio, Texas. Dr. Brenner is highly rated in 18 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri.

Expertise in
9
conditions
Hematology | Oncology
Expertise in
9
conditions
Hematology | Oncology

Methodist Children's Hospital Cancer And Blood Center

4410 Medical Dr Ste 550, 
San Antonio, TX 
 (0.6 miles away)
Languages Spoken:
English
Accepting New Patients

Ghadir Sasa is a Hematologist and an Oncologist in San Antonio, Texas. Dr. Sasa is highly rated in 9 conditions, according to our data. Her top areas of expertise are Dyskeratosis Congenita, Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Anemia, and Bone Marrow Transplant. Dr. Sasa is currently accepting new patients.

Frequently Asked Questions about Dr. Vinod Gidvani

How do I make an appointment with Dr. Vinod Gidvani?

You can book an appointment with Dr. Vinod Gidvani by calling their office at 210-575-6240. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vinod Gidvani a top-rated expert for Dyserythropoietic Anemia and Thrombocytopenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vinod Gidvani is classified as an Advanced expert for Dyserythropoietic Anemia and Thrombocytopenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vinod Gidvani specialize in?

While Dr. Vinod Gidvani is a Hematology, they have specific expertise in Dyserythropoietic Anemia and Thrombocytopenia, Langerhans Cell Histiocytosis, and Hepatoblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Vinod Gidvani participate in research or clinical trials?

Yes. Dr. Vinod Gidvani has published 3 articles and abstracts on conditions like Dyserythropoietic Anemia and Thrombocytopenia. You can view a list of Dr. Vinod Gidvani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vinod Gidvani accept my insurance?

Dr. Vinod Gidvani accepts most major insurance plans, including Friday Health and Humana. We recommend calling the office directly at 210-575-6240 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gidvani's expertise for a condition
ConditionClose
      View All 16 Advanced Conditions
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile